Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor replacement presented as an intravenous formulation for use in patients with inherited or acquired deficiencies of factor IX. It is employed to treat Hemophilia B and acquired factor IX deficiency by restoring normal clotting function.

GNH USA supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to strict quality standards and providing reliable global distribution.

Immunine is used to replace deficient factor IX in the intrinsic coagulation pathway for several clinical conditions.

Hemophilia B: restores clotting ability and reduces bleeding episodes in patients with congenital factor IX deficiency. Acquired factor IX deficiency: corrects the deficiency caused by liver disease, vitamin K antagonists, or inhibitors, supporting hemostasis. Surgical prophylaxis in factor IX‑deficient patients: provides adequate clotting factor levels to prevent peri‑operative bleeding.

Immunine may be associated with a range of adverse reactions following intravenous infusion.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, chills) - Headache - Fever - Nausea - Arthralgia

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Development of neutralizing antibodies (inhibitors) against factor IX - Thrombotic events such as deep‑vein thrombosis - Transmission of infectious agents (viral contamination)

When using Immunine, clinicians should observe several safety measures to minimize risks.

Inhibitor monitoring: regularly test for anti‑factor IX antibodies that can reduce efficacy. Allergy assessment: screen for prior hypersensitivity to plasma proteins or recombinant factor IX. Concomitant anticoagulants: evaluate bleeding risk if patient is receiving warfarin or heparin. Liver function: assess hepatic status as it may affect factor metabolism. Surgical planning: ensure adequate factor levels are achieved before invasive procedures. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine can interact with other medicines that affect hemostasis or immune response.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, direct oral anticoagulants): may diminish the hemostatic effect of factor IX. - Other pro‑coagulant agents (e.g., activated prothrombin complex concentrates): increase risk of thrombosis. - Immunosuppressive biologics: may alter inhibitor development.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., aminoglycosides): may affect plasma protein binding. - Antifibrinolytics (e.g., tranexamic acid): may enhance clot stability, requiring dose adjustment. - Live‑attenuated vaccines: monitor for immune reactions.